Busser Hélène, De Bruyn Cécile, Urbain Frédéric, Najar Mehdi, Pieters Karlien, Raicevic Gordana, Meuleman Nathalie, Bron Dominique, Lagneaux Laurence
1 Laboratory of Clinical Cell Therapy, Jules Bordet Institut, Université Libre de Bruxelles, Brussels, Belgium .
Stem Cells Dev. 2014 Oct 1;23(19):2390-400. doi: 10.1089/scd.2014.0071. Epub 2014 Jul 3.
Stem cell therapy is a potential method for the treatment of numerous diseases. The most frequent cellular source is bone-marrow-derived mesenchymal stromal cells (BM-MSCs). Human adipose-derived stromal cells (ADSCs) share similar properties with BM-MSCs as they support hematopoiesis, modulate ongoing immune responses, and differentiate into cells of mesodermal origin. On the other hand, ADSCs have higher frequency in situ, higher availability, and very few ethical issues compared with BM-MSCs, giving them an advantage over BM-MSCs for clinical use. Most of the methods used to isolate ADSCs contain a collagenase digestion step, but the type of collagenase and time of sample digestion vary among studies and these differences could have an impact on the cell properties and thus in result comparison. To overcome this obstacle, we propose a new method to isolate ADSCs from lipoaspirate without collagenase digestion step. We compared ADSCs obtained with our method versus classical protocol using collagenase digestion. Cells obtained with our method are equivalent but they have a better long-term hematopoietic support than those obtained with classical method. Moreover, our method has an advantage over the classical one as it is easier, safer, faster, less expensive, and more consistent with good manufacturing practices to obtain large number of ADSCs ex vivo.
干细胞疗法是治疗多种疾病的一种潜在方法。最常见的细胞来源是骨髓间充质基质细胞(BM-MSCs)。人脂肪来源的基质细胞(ADSCs)与BM-MSCs具有相似的特性,因为它们支持造血、调节正在进行的免疫反应,并分化为中胚层来源的细胞。另一方面,与BM-MSCs相比,ADSCs原位频率更高、可用性更高,且伦理问题极少,这使得它们在临床应用中优于BM-MSCs。大多数用于分离ADSCs的方法都包含胶原酶消化步骤,但不同研究中胶原酶的类型和样本消化时间各不相同,这些差异可能会影响细胞特性,从而影响结果比较。为克服这一障碍,我们提出了一种无需胶原酶消化步骤即可从抽脂物中分离ADSCs的新方法。我们将用我们的方法获得的ADSCs与使用胶原酶消化的经典方案获得的ADSCs进行了比较。用我们的方法获得的细胞是等效的,但它们比用经典方法获得的细胞具有更好的长期造血支持能力。此外,我们的方法比经典方法更具优势,因为它更容易、更安全、更快、成本更低,并且在体外获得大量ADSCs时更符合良好生产规范。